Статья
СОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О ПЕРИПАРТАЛЬНОЙ КАРДИОМИОПАТИИ — ОПРЕДЕЛЕНИЕ, ЭПИДЕМИОЛОГИЯ, ПАТОГЕНЕЗ (ЧАСТЬ I)
В первой части обзора, посвященного перипартальной кардиомиопатии, обсуждаются вопросы определения заболевания, его распространенности по данным различных эпидемиологических исследований, проведенных в различных странах. Подробное внимание уделено факторам риска заболевания, в частности возрастному акушерскому анамнезу, беременностью двойней и более, токололитической терапии, курению, артериальной гипертензии и др. Обсуждаются сложные вопросы этиопатогенеза заболевания, включая миокардит, роль системы пролактин-катепсин-пролактин 16 кDa, нарушение питания, дефицит селена, генетическую предрасположенность на фоне патологического ответа на гемодинамический стресс во время беременности.
1. Lewis GE. Saving mothers’ lives: reviewing maternal deaths to make motherhood safer: 2006–2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG. 2011; 118: 1-203.
2. Huisman CM, Zwart JJ, Roos-Hesselink JW, et al. Incidence and predictors of maternal cardiovascular mortality in the Netherlands: a prospective cohort study. PLoS ONE. 2013; 8: e56494. doi:10.1371/journal.pone.0056494.
3. Roos-Hesselink JW, Duvekot JJ, Thorne SA. Pregnancy in high risk cardiac conditions. Heart. 2009; 95: 680-6. doi: 10.1136/hrt.2008.148932.
4. Gelson E, Gatzoulis M, Steer P, et al. Heart disease — why is maternal mortality increasing? BJOG. 2009; 116: 609–611. doi: 10.1111/j.1471-0528.2008.02082.x.
5. Berg CJ, Chang J, Callaghan WM, et al. Pregnancy-related mortality in the United States, 1998 to 2005. Obstet. Gynecol. 2010; 116: 1302-9.
6. Schutte JM, Steegers EA, Schuitemaker NW, et al. Rise in maternal mortality in the Netherlands. BJOG. 2010; 117: 399-406. doi: 10.1111/j.1471-0528.2009.02382.x.
7. Esscher A, Högberg U, Haglund B, et al. Maternal mortality in Sweden 1988–2007: more deaths than officially reported. Acta Obstet. Gynecol. Scand. 2013; 92: 40-6. doi: 10.1111/ aogs.12037.
8. Johnson-Coyle L, Jensen L, Sobey A. Peripartum cardiomyopathy: review and practice guidelines. Amer. J. Crit. Care. 2012; 21: 89-98. doi: 10.4037/ajcc2012163
9. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from Heart Failure Association of European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur. J. Heart Failure. 2010; 12: 767-78.
10. Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 2000; 283: 1183-8.
11. Медведь В. И., Давыдова Ю. В. Перипартальная кардиомиопатия как бидисциплинарная проблема. Серцева недостатнiсть. 2011; 1: 94-7.
12. Elkayam U, Akhter M.W, Singh H, et al. Pregnancy-associated cardiomyopathy. Clinical characteristics and a comparison between early and late presentation. Circulation. 2005; 111: 2050-5.
13. Richie C. Clinical contribution to the pathology, diagnosis and treatment of certain chronic diseases of the heart. Edinb. Med. Surg. J. 1849; 2: 333-42.
14. Gouley BA, McMillan TM, Bellet S. Idiopathic myocardial degeneration associated with pregnancy and especially the puerperium. Amer. J. Med. Scien. 1937; 19: 185-99.
15. Hull E, Hafkesbring E. “Toxic” postpartum heart disease. New Orleans Med. Surg. J. 1937; 89: 550.
16. Mishra VN, Mishra N, Devanshi. Peripartum cardiomyopathy. JAPI. 2013; 61; 268-73.
17. Okeke TC, Ezenyeaku CCT, Ikeako LC. Peripartum cardiomyopathy. Ann. Med. Health Sci. Res. 2013; 3(3): 313-9.
18. Blauwet LA, Cooper LT. Diagnosis and management of peripartum cardiomyopathy. Heart. 2011; 97: 1970-1981. doi: 10.1136/heartjnl-2011-300349.
19. Pyatt JR, Dubey G. Peripartum cardiomyopathy: current understanding, comprehensive management review and new developments. Postgrad. Med. J. 2010; 87: 34-9.
20. Bhattacharyya A, Basra SS, Sen P, et al. Peripartum cardiomyopathy: a review. Tex. Heart Inst. J. 2012; 39(1): 8-16.
21. Zhang F. The research into the clinical characteristics of peripartum cardiomyopathy. Heart. 2012; 98: 165-6. doi:10.1136/heartjnl-2012-302920j.17
22. Lok SI, Kirkels JH, Klöpping C, et al. Peripartum cardiomyopathy: the need for a national database. Neth. Heart J. 2011; doi 10.1007/s12471-011-0083-7.
23. Givertz MM. Peripartum cardiomyopathy. Circulation. 2013; 127: e622-e626. doi:10.1161/ CIRCULATIONAHA. 113.001851.
24. Gunderson EP, Croen LA, Chiang V, et al. Epidemiology of peripartum cardiomyopathy. 2011; 118 (3): 583-591. doi: 10.1097/AOG.0b013e318229e6de.
25. Sliwa K, Föster O, Libhaber E, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur. Heart J. 2006; 27: 441-6.
26. Lapaire O, Hosli I, Zanetti-Daellenbach R, et al. Impact of fetal-maternal microchimerism on women’s health a review. J. Matern. Fetal Neonatal. Med. 2007; 20(1): 1-5.
27. Lamparter S, Pankuweit S, Maisch B. Clinical and immunological characteristics in peripartum cardiomyopathy. Int. J. Cardiol. 2007; 118: 14-20.
28. Warraich RS, Sliwa K, Damasceno A, et al. Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy. Amer. Heart J. 2005; 150: 263-9.
29. Bultmann BD, Klingel K, Nabauer M, et al. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Amer. J. Obstet. Gynecol. 2005; 193: 363-5.
30. Fett JD. Viral infection as a possible trigger for the development of peripartum cardiomyopathy. Int. J. Gynaecol. Obstet. 2007; 97: 149-50.
31. Hilfiker-Kleiner D, Sliwa K, Drexler H. Peripartum cardiomyopathy: into recent insight its pathophysiology. Trends Cardiovasc. Med. 2008; 18: 173-9.
32. Hilfiker-Kleiner D, Meyer GP, Schieffer E, et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J. Amer. Coll. Cardiol. 2007; 50; 2354-5.
33. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin derived 16kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007; 128: 589-600.
34. Yamac H, Bultmann I, Sliwa K, et al. Prolactin: a new therapeutic target in peripartum cardiomyopathy. Heart. 2010; 96: 1352-7.
35. Habedank D, Kuhenle Y, Elgeti T, et al. Recovery from peripartum cardiomyopathy after treatment with bromocriptine. Eur. J. Heart Failure. 2008; 10: 1149-51.
36. De Jong JS, Rietveld K, Van Lochem LT, et al. Rapid left ventricular recovery after cabergoline treatment in a patient with peripartum cardiomyopathy. Eur. J. Heart Failure. 2009; 11: 220-2.
37. Halkein J, Tabruyn SP, Ricke-Hoch M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J. Clin. Invest. 2013; 123(5): 2143-54. doi:10.1172/JCI64365.
38. Walenta K, Schwarz V, Schrimer SH, et al. Circulating microparticles as indicators of peripartum cardiomyopathy. Eur. Heart J. 2012; 33(12): 1469-79. doi: 10.1093/eurheartj/ehr485.
39. Wu Z-H, Ji C-L, Li H, et al. Membrane microparticles and diseases. Eur. Rev. Med. Pharm. Scien. 2013; 17: 2420-7.
40. Fett JD, Sundstrom JB, Etta King M, et al.Mother-daughter peripartum cardiomyopathy. Inter. J. Cardiol. 2002; 86: 331-2.
41. Meyer GP, Labidi S, Podewski E, et al. Bromocriptine treatment associated with recovery from peripartum cardiomyopathy in siblings: two case reports. J. Med. Case Reports. 2010; 4: 80.
42. Van Spaendock-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation. 2010; 121: 2169-75.
43. Morales A, Painter T, Li R, et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation. 2010; 121: 2176-82.
44. Karamermer Y, Roos-Hesselink JW. Pregnancy and adult congenital heart disease. Expert Rev. Cardiovasc. Ther. 2007; 5: 859-69.
45. Geva T, Mauer MB, Striker L, et al. Effects of physiologic load of pregnancy on left ventricular contractility and remodeling. Amer. Heart J 1997; 133: 53-9.
46. Cénac A, Simonoff M, Moretto P, et al. A low plasma selenium is a risk factor for peripartum cardiomyopathy: a comparative study in Sahelian Africa. Int. J Cardiol. 1992; 36(1): 57-9.
47. Fett J, Ansara A, Sundstrom J, et al. Peripartum cardiomyopathy: a selenium disconnection and an autoimmune connection. Int. J Cardiol. 2002; 86(2): 311-6.
48. Ntusi NB, Mayosi BM. Aetiology and risk factors of peripartum cardiomyopathy: a systematic review. Int J Cardiol. 2009; 131(2): 168-79.
49. Schleußner E. The prevention, diagnosis and treatment of premature labor. Dtsch. Arztebl. Int. 2013; 110(13): 227-36.